Reliance Global Group Inc SEC Filings

Reliance Global Group, Inc. approved and implemented a 1-for-40 reverse stock split of its common stock to help regain compliance with Nasdaq’s $1.00 minimum bid price requirement. The amendment to the articles of incorporation is scheduled to become effective at 5:00 p.m. Eastern on May 15, 2026.

Every 40 existing shares will convert into one share, reducing the amount of common stock outstanding from approximately 22,230,563 shares to 555,764 shares, while authorized common shares will be set at 50 million and par value stays at $0.086 per share. Trading on a split-adjusted basis on the Nasdaq Capital Market under the symbol EZRA and new CUSIP 75946W504 is expected to begin on May 18, 2026, with each shareholder’s ownership percentage remaining the same.

Reliance Global Group (Nasdaq: EZRA) reported a first‑quarter 2026 net loss of $1.47 million, narrowing from $1.74 million a year earlier, as it continued reshaping its portfolio and cost structure. Commission revenue declined about 10% to $3.83 million, mainly due to selling several agencies in 2025, partly offset by roughly 11% organic growth in remaining businesses.

Operating expenses fell to $5.07 million from $5.64 million, but non‑GAAP AEBITDA turned to a loss of $0.43 million from a positive $0.15 million, largely because equity‑based compensation was much lower in 2026 and therefore added back less. Cash and restricted cash rose to $3.24 million with working capital of about $2.60 million and stockholders’ equity of $7.42 million.

The company invested about $0.50 million in Enquantum, taking a roughly 23.8% stake and recording an equity‑method loss of about $26,000. It also completed a public offering providing roughly $2.0 million in gross proceeds and realized about $0.84 million from warrant exercises, while modestly using its at‑the‑market program.

Subsequent to quarter‑end, Reliance formed majority‑owned LifeSci Global Group to invest about $2.0 million in Innervate Radiopharmaceuticals and expanded its equity line of credit to $50.0 million, with about $49.1 million remaining. The board approved a 1‑for‑40 reverse stock split to help regain compliance with Nasdaq’s $1.00 minimum bid price requirement, highlighting listing risk alongside the company’s push into technology and life sciences through its EZRA International Group and Scale51 strategy.

Reliance Global Group (Nasdaq: EZRA) reported a first‑quarter 2026 net loss of $1.47 million, narrowing from $1.74 million a year earlier, as it continued reshaping its portfolio and cost structure. Commission revenue declined about 10% to $3.83 million, mainly due to selling several agencies in 2025, partly offset by roughly 11% organic growth in remaining businesses.

Operating expenses fell to $5.07 million from $5.64 million, but non‑GAAP AEBITDA turned to a loss of $0.43 million from a positive $0.15 million, largely because equity‑based compensation was much lower in 2026 and therefore added back less. Cash and restricted cash rose to $3.24 million with working capital of about $2.60 million and stockholders’ equity of $7.42 million.

The company invested about $0.50 million in Enquantum, taking a roughly 23.8% stake and recording an equity‑method loss of about $26,000. It also completed a public offering providing roughly $2.0 million in gross proceeds and realized about $0.84 million from warrant exercises, while modestly using its at‑the‑market program.

Subsequent to quarter‑end, Reliance formed majority‑owned LifeSci Global Group to invest about $2.0 million in Innervate Radiopharmaceuticals and expanded its equity line of credit to $50.0 million, with about $49.1 million remaining. The board approved a 1‑for‑40 reverse stock split to help regain compliance with Nasdaq’s $1.00 minimum bid price requirement, highlighting listing risk alongside the company’s push into technology and life sciences through its EZRA International Group and Scale51 strategy.

Reliance Global Group, Inc. reported results from its 2026 Annual Meeting of Stockholders, held via live webcast. As of March 5, 2026, there were 21,253,013 common shares outstanding and entitled to vote, and 9,591,634 shares were represented, about 45.13% of those eligible.

Stockholders elected five directors to serve until the 2027 annual meeting and ratified Urish Popeck & Co., LLC as independent auditor for the year ending December 31, 2026. Each director nominee received over 3.27 million votes for, with substantial broker non-votes.

Investors also approved an amendment to the 2025 Equity Incentive Plan, increasing shares available for issuance by 14,000,000, from 2,000,000 to 16,000,000. In a separate proposal, stockholders approved issuing common shares in excess of the Nasdaq Exchange Cap under a Common Stock Purchase Agreement dated August 26, 2025, as amended.

Reliance Global Group, Inc. reported results from its 2026 Annual Meeting of Stockholders, held via live webcast. As of March 5, 2026, there were 21,253,013 common shares outstanding and entitled to vote, and 9,591,634 shares were represented, about 45.13% of those eligible.

Stockholders elected five directors to serve until the 2027 annual meeting and ratified Urish Popeck & Co., LLC as independent auditor for the year ending December 31, 2026. Each director nominee received over 3.27 million votes for, with substantial broker non-votes.

Investors also approved an amendment to the 2025 Equity Incentive Plan, increasing shares available for issuance by 14,000,000, from 2,000,000 to 16,000,000. In a separate proposal, stockholders approved issuing common shares in excess of the Nasdaq Exchange Cap under a Common Stock Purchase Agreement dated August 26, 2025, as amended.

Reliance Global Group formed LifeSci Global Group LLC, a majority-owned healthcare investment vehicle, and funded it using a Promissory Note of up to $2,000,000 from its subsidiary EZRA International Group.

LifeSci Global agreed to purchase up to 421,053 Innervate Radiopharmaceuticals units at $4.75 per unit, totaling about $2.0 million, with $500,000 funded at closing. The deal includes priority distributions and up to 210,526 warrants and was approved by independent directors as a related-party transaction, with committee reshuffling to ensure board independence.

Reliance Global Group formed LifeSci Global Group LLC, a majority-owned healthcare investment vehicle, and funded it using a Promissory Note of up to $2,000,000 from its subsidiary EZRA International Group.

LifeSci Global agreed to purchase up to 421,053 Innervate Radiopharmaceuticals units at $4.75 per unit, totaling about $2.0 million, with $500,000 funded at closing. The deal includes priority distributions and up to 210,526 warrants and was approved by independent directors as a related-party transaction, with committee reshuffling to ensure board independence.

Reliance Global Group, Inc. Chairman and CEO Ezra Beyman reported an open-market purchase of 300,000 shares of Common Stock at a price of 0.1699 per share. Following this transaction, he directly holds 959,299.997 shares, with additional smaller indirect holdings through YES Americana Group, LLC and Reliance Global Holdings, LLC.

Reliance Global Group, Inc. Chairman and CEO Ezra Beyman reported an open-market purchase of 300,000 shares of Common Stock at a price of 0.1699 per share. Following this transaction, he directly holds 959,299.997 shares, with additional smaller indirect holdings through YES Americana Group, LLC and Reliance Global Holdings, LLC.

Reliance Global Group, Inc. filed an amendment to its annual report for the year ended December 31, 2025 to correct the list of exhibits. The company had inadvertently omitted its Compensation Recovery Policy dated November 13, 2023, which is now added as Exhibit 97.1.

The amendment also includes current-dated CEO and CFO certifications under Section 302 of the Sarbanes-Oxley Act but makes no changes to the financial statements or other disclosures in the original report. As of March 10, 2026, the company had 21,253,013 common shares outstanding, and non-affiliate common stock held a market value of about $5.3 million as of June 30, 2025.

Reliance Global Group, Inc. filed an amendment to its annual report for the year ended December 31, 2025 to correct the list of exhibits. The company had inadvertently omitted its Compensation Recovery Policy dated November 13, 2023, which is now added as Exhibit 97.1.

The amendment also includes current-dated CEO and CFO certifications under Section 302 of the Sarbanes-Oxley Act but makes no changes to the financial statements or other disclosures in the original report. As of March 10, 2026, the company had 21,253,013 common shares outstanding, and non-affiliate common stock held a market value of about $5.3 million as of June 30, 2025.

Reliance Global Group, Inc. Chief Financial Officer Joel Markovits reported an open-market sale of common stock. On March 24, 2026, he sold 127,562 shares of Reliance Global common stock at an average price of $0.2055 per share. Following this transaction, he directly owns 127.59 shares of the company’s common stock.

Reliance Global Group, Inc. Chief Financial Officer Joel Markovits reported an open-market sale of common stock. On March 24, 2026, he sold 127,562 shares of Reliance Global common stock at an average price of $0.2055 per share. Following this transaction, he directly owns 127.59 shares of the company’s common stock.

Reliance Global Group is asking stockholders to approve several key items at its virtual 2026 annual meeting on May 6, 2026. Holders of 21,253,013 common shares as of March 5, 2026 can vote.

Stockholders will vote to elect five directors, ratify Urish Popeck & Co., LLC as auditor for 2026, and amend the 2025 Equity Incentive Plan to raise the share pool from 2,000,000 to 16,000,000 shares. They are also asked to approve, for Nasdaq Listing Rule 5635(d) purposes, the potential issuance of common stock under a $50,000,000 equity line of credit with White Lion Capital. This arrangement contemplates up to 11,407,273 shares, described as approximately 54% of shares outstanding as of March 12, 2026, subject to pricing, caps and ownership limits. A separate proposal would allow adjournment of the meeting to solicit additional proxies if needed.

The Board unanimously recommends voting in favor of all proposals and outlines executive and director compensation, governance structure, insider ownership of 6.33% by directors and officers as a group, and late Section 16 filings by certain insiders.

Reliance Global Group is asking stockholders to approve several key items at its virtual 2026 annual meeting on May 6, 2026. Holders of 21,253,013 common shares as of March 5, 2026 can vote.

Stockholders will vote to elect five directors, ratify Urish Popeck & Co., LLC as auditor for 2026, and amend the 2025 Equity Incentive Plan to raise the share pool from 2,000,000 to 16,000,000 shares. They are also asked to approve, for Nasdaq Listing Rule 5635(d) purposes, the potential issuance of common stock under a $50,000,000 equity line of credit with White Lion Capital. This arrangement contemplates up to 11,407,273 shares, described as approximately 54% of shares outstanding as of March 12, 2026, subject to pricing, caps and ownership limits. A separate proposal would allow adjournment of the meeting to solicit additional proxies if needed.

The Board unanimously recommends voting in favor of all proposals and outlines executive and director compensation, governance structure, insider ownership of 6.33% by directors and officers as a group, and late Section 16 filings by certain insiders.

Reliance Global Group, Inc. entered into two settlement agreements to resolve disputes tied to prior stock purchase transactions. The company will pay a cash settlement of $90,560 under the Rubin Settlement Agreement and $40,350 under the Kreindler Settlement Agreement, after which all related obligations are fully released.

The company also amended its Common Stock Purchase Agreement with White Lion Capital to extend the investment commitment period through the earlier of reaching the commitment amount or December 31, 2028, and increased the commitment amount to $50,000,000. In addition, Reliance Global Group adopted amended and restated bylaws to give the board flexibility in setting annual meeting dates and filed Articles of Restatement that restate its articles of incorporation in full.

Reliance Global Group, Inc. entered into two settlement agreements to resolve disputes tied to prior stock purchase transactions. The company will pay a cash settlement of $90,560 under the Rubin Settlement Agreement and $40,350 under the Kreindler Settlement Agreement, after which all related obligations are fully released.

The company also amended its Common Stock Purchase Agreement with White Lion Capital to extend the investment commitment period through the earlier of reaching the commitment amount or December 31, 2028, and increased the commitment amount to $50,000,000. In addition, Reliance Global Group adopted amended and restated bylaws to give the board flexibility in setting annual meeting dates and filed Articles of Restatement that restate its articles of incorporation in full.